ProShare Advisors
AXSM icon

ProShare Advisors’s Axsome Therapeutics AXSM Stock Holding History

ProShare Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$335K Buy
1,816
+131
+8% +$28.5K ﹤0.01% 1265
2026
Q2 		$412K Sell
1,685
-6,611
-80% -$1.43M ﹤0.01% 1213
2026
Q1 		$1.4M Sell
8,296
-1,434
-15% -$248K ﹤0.01% 730
2025
Q4 		$1.78M Buy
9,730
+1,032
+12% +$144K ﹤0.01% 708
2025
Q3 		$1.06M Sell
8,698
-1,440
-14% -$162K ﹤0.01% 794
2025
Q2 		$1.06M Sell
10,138
-32
-0.3% -$3.39K ﹤0.01% 800
2025
Q1 		$1.19M Sell
10,170
-2,494
-20% -$284K ﹤0.01% 772
2024
Q4 		$1.07M Buy
12,664
+2,942
+30% +$271K ﹤0.01% 880
2024
Q3 		$874K Buy
9,722
+2,015
+26% +$176K ﹤0.01% 853
2024
Q2 		$620K Sell
7,707
-2,017
-21% -$149K ﹤0.01% 871
2024
Q1 		$776K Buy
9,724
+800
+9% +$67.1K ﹤0.01% 869
2023
Q4 		$710K Buy
8,924
+1,268
+17% +$84.8K ﹤0.01% 858
2023
Q3 		$535K Buy
7,656
+558
+8% +$41.7K ﹤0.01% 893
2023
Q2 		$510K Buy
7,098
+309
+5% +$22.8K ﹤0.01% 945
2023
Q1 		$419K Sell
6,789
-926
-12% -$60.8K ﹤0.01% 994
2022
Q4 		$595K Buy
7,715
+1,047
+16% +$62.6K ﹤0.01% 883
2022
Q3 		$297K Buy
6,668
+415
+7% +$20.7K ﹤0.01% 1160
2022
Q2 		$239K Sell
6,253
-2,865
-31% -$90.6K ﹤0.01% 1352
2022
Q1 		$378K Sell
9,118
-2,265
-20% -$70.2K ﹤0.01% 1476
2021
Q4 		$430K Sell
11,383
-225
-2% -$8.28K ﹤0.01% 1563
2021
Q3 		$383K Sell
11,608
-2,350
-17% -$91.6K ﹤0.01% 1374
2021
Q2 		$942K Buy
13,958
+1,386
+11% +$83.2K ﹤0.01% 1074
2021
Q1 		$712K Buy
12,572
+672
+6% +$47.3K ﹤0.01% 1206
2020
Q4 		$969K Buy
11,900
+2,498
+27% +$187K ﹤0.01% 898
2020
Q3 		$670K Sell
9,402
-291
-3% -$22.7K ﹤0.01% 834
2020
Q2 		$798K Buy
9,693
+3,365
+53% +$259K ﹤0.01% 777
2020
Q1 		$372K Sell
6,328
-4,545
-42% -$370K ﹤0.01% 810
2019
Q4 		$1.12M Buy
+10,873
New +$439K 0.01% 767

Other funds holding AXSM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

ProShare Advisors's AXSM Position: Q3 2026 in Review

ProShare Advisors increased its Axsome Therapeutics (AXSM) stake by 7.8% in Q3 2026, buying an estimated $28.5K and bringing the position to 1,816 shares worth $335K. The position accounts for ﹤0.01% of the portfolio, ranked #1265.

ProShare Advisors first reported a position in AXSM in Q4 2019 and has held it in 28 quarters since. The position peaked at $1.78M in Q4 2025. 242 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • ProShare Advisors held 1,816 shares of Axsome Therapeutics worth $335K as of Q3 2026.
  • ProShare Advisors bought 131 Axsome Therapeutics shares in Q3 2026, an estimated $28.5K.
  • Axsome Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q3 2026, its #1265 holding.
  • ProShare Advisors first reported a position in Axsome Therapeutics in Q4 2019 and has held it in 28 quarters since.
  • ProShare Advisors's Axsome Therapeutics position peaked at $1.78M in Q4 2025.
  • 242 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on ProShare Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.